Cover Image
市場調查報告書

在PharmaPoint:B型肝炎病毒(HBV)預防疫苗--日本的醫藥品的預測與市場分析

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Japan Drug Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 298834
出版日期 內容資訊 英文 89 Pages
訂單完成後即時交付
價格
Back to Top
在PharmaPoint:B型肝炎病毒(HBV)預防疫苗--日本的醫藥品的預測與市場分析 PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Japan Drug Forecast and Market Analysis to 2022
出版日期: 2014年01月31日 內容資訊: 英文 89 Pages
簡介

全球有20億人感染B型肝炎病毒(HBV),每年都有60萬人因B型肝炎相關肝疾病而死亡。自混合HBsAg疫苗出現以來,這二十年來大幅減輕了這個疾病帶來的負擔,但仍留有成人的疫苗攝取及有效性(尤其是特殊病患上)的問題。一般認為今後高風險成人患者的高血清轉換率的達成、各國政策上的對策,都會推動市場的成長。但日本幾乎沒有定期預防接種的計劃,此外也未對成人高風險集團進行預防接種。日本政府雖然對於疫苗的接種態度積極,但一般預測HBV預防疫苗接種率在近年僅將微微上升,這將成為限制市場成長的要因。

本報告提供日本的B型肝炎病毒(HBV)預防疫苗相關的最新研究·開發情形及相關市場未來展望分析,彙整疾病概要和治療方法,市場機會及未滿足需求,市場規模趨勢(今後10年份),已上市的主要的疫苗簡介,日本市場現狀與今後的方向性等資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 概要
  • 病因與病情
    • 病因
    • 病理
  • 症狀
  • 預測

第4章 疫苗的接種宣導與攝取率

  • 概要
  • 日本
    • 預防接種的建議與政策
    • 攝取率
    • 臨床診療

第5章 競爭環境

  • 概要
  • 競爭企業的策略性評估
  • 產品簡介:單價疫苗
    • Recombivax HB
    • Bimmugen
  • 產品簡介:混合疫苗

第6章 市場機會及未滿足需求

  • 概要
  • 疫苗免疫抗原性的增加
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 疫苗接種率的上升
  • 患者意識的提升
  • 醫生教育的改善
  • 成本效益高的疫苗

第7章 市場預測

  • 日本
    • 市場預測
    • 市場促進·阻礙因素

第8章 附錄

圖表一覽

目錄
Product Code: GDHC216CFR

Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.

Similar to the situation in the UK, sales in the Japanese market are severely constrained by the absence of a routine HBV immunization program. Furthermore, Japan also does not target adult risk groups for HBV immunization, an approach that is unique among the eight markets discussed in this report. While Japanese policymakers have hinted at a more pro-vaccine stance, GlobalData does not expect HBV immunization recommendations to be expanded in Japan during the forecast period, which poses a serious barrier to market growth.

Scope

  • Overview of Hepatitis B disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Japan from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the Japan Hepatitis B disease market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis B disease
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in Japan

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Overview
  • 3.2. Etiology and Pathophysiology
    • 3.2.1. Etiology
    • 3.2.2. Pathophysiology
  • 3.3. Symptoms
  • 3.4. Prognosis

4. Vaccination Recommendations and Coverage Rates

  • 4.1. Overview
  • 4.2. Japan
    • 4.2.1. Immunization Recommendations and Policies
    • 4.2.2. Vaccination Coverage
    • 4.2.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Monovalent Vaccines
    • 5.3.1. Recombivax HB
    • 5.3.2. Bimmugen
  • 5.4. Product Profiles - Combination Vaccines

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Increased Vaccine Immunogenicity
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Increased Vaccination Coverage Rates
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Increased Patient Awareness
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Improved Physician Education
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. More Cost-Effective Vaccines
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity

7. Market Outlook

  • 7.1. Japan
    • 7.1.1. Forecast
    • 7.1.2. Drivers and Barriers

8. Appendix

  • 8.1. Bibliography
  • 8.2. Abbreviations
  • 8.3. Methodology
  • 8.4. Forecasting Methodology
    • 8.4.1. Patient Populations Targeted for Vaccination
    • 8.4.2. Vaccination Coverage Rates
    • 8.4.3. Vaccinated Patients
    • 8.4.4. Regulatory Approval vs. Advisory Committee Recommendation
    • 8.4.5. Vaccines Included
    • 8.4.6. Key Launch Dates
    • 8.4.7. General Pricing Assumptions
    • 8.4.8. Individual Vaccine Assumptions
  • 8.5. Physicians and Specialists Included in this Study
    • 8.5.1. Interviews of Key Opinion Leaders (KOLs)
    • 8.5.2. Online Survey of High-Prescribing Physicians (non-KOLs)
  • 8.6. About the Authors
    • 8.6.1. Analyst
    • 8.6.2. Therapy Area Director
    • 8.6.3. Global Head of Healthcare
  • 8.7. About GlobalData
  • 8.8. Disclaimer

List of Tables

  • Table 1: Modes of HBV Transmission
  • Table 2: HBV Serological Markers and Test Interpretations
  • Table 3: Symptoms of HBV Infection
  • Table 4: HBV Vaccination Advisory Committees by Country
  • Table 5: HBV Immunization Recommendations by Country
  • Table 6: Targeted Age Group(s) for Routine Immunization and Most Administered HBV Vaccines by Country in the Global Markets, 2014
  • Table 7: Leading Vaccines for HBV, 2014
  • Table 8: Product Profile - Recombivax HB
  • Table 9: Immunogenicity Profile - Recombivax HB
  • Table 10: Safety Profile - Recombivax HB
  • Table 11: Recombivax HB SWOT Analysis, 2014
  • Table 12: Product Profile - Bimmugen
  • Table 13: Bimmugen SWOT Analysis, 2014
  • Table 14: Unmet Need and Opportunity in Prophylactic HBV Vaccines
  • Table 15: Sales Forecasts ($) for HBV Vaccines in Japan, 2012-2022
  • Table 16: Japan HBV Vaccine Market - Drivers and Barriers, 2014
  • Table 17: Patient Population(s) Targeted for HBV Vaccination in the Pediatric Market, Japan
  • Table 18: Key Launch Dates
  • Table 19: High-Prescribing Physicians (non-KOLs) Surveyed, Japan

List of Figures

  • Figure 1: HBV Structure and the Recombinant Vaccine Development Process
  • Figure 2: High-Prescriber Estimation of Pediatric HBV Vaccine Patient Share in Japan, 2014
  • Figure 3: Sales for HBV Vaccines in Japan, 2012-2022
Back to Top